effect of collagenase enzyme in scleroderma
Phase 2
Recruiting
- Conditions
- systemic scleroderma.Systemic sclerosis [scleroderma]
- Registration Number
- IRCT20140624018210N11
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 17
Inclusion Criteria
Patients should have at least one active scleroderma lesion
Exclusion Criteria
Patients who have received or inhaled oral prostanoids in the past 3 months.
Phosphodiesterase inhibitors have been used in the past month.
Take antibiotics 2 weeks before the study.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Qualitative intensity of scleroderma. Timepoint: Before treatment and 3 months after treatment. Method of measurement: Patient complaint, objective evaluation by a physician.
- Secondary Outcome Measures
Name Time Method Quantitative intensity of scleroderma. Timepoint: Before treatment, three months after treatment. Method of measurement: Determine the size of the lesions with visioface, determine the location and number of lesions.;The rate of improvement of scleroderma. Timepoint: Before treatment, three months after treatment. Method of measurement: Patient satisfaction, visioface photography, physician diagnosis.;Adverse events. Timepoint: Before treatment, three months after treatment. Method of measurement: Patient report, Physician diagnosis.